AB Science Release: Masitinib is Being Investigated in the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: Nov 05, 2013
PARIS, Nov. 4, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a clinical development program with masitinib in the treatment of Amyotrophic Lateral Sclerosis (ALS).
Help employers find you! Check out all the jobs and post your resume.